Answers are grounded in this paper and cite their sources.
Post-treatment ctDNA positivity is associated with recurrence risk across solid tumors, but detecting molecular disease earlier does not necessarily identify an intervention that improves outcomes ...
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: